Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

{
  "signal_id": "20f6da2e-43b3-61da-21d2-bf8b77b9bf2f",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-29T12:38:46+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.hcplive.com/view/semaglutide-2-mg-escalation-tied-to-lower-mace-vs-tirzepatide-switch-in-t2d",
    "title": "Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D - HCPLive",
    "excerpt": "In a retrospective US claims analysis, adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg had a 6% lower adjusted MACE risk than those who switched to tirzepatide, according to Novo Nordisk (adjusted HR, 1.06; 95% CI, 1.04–1.08). No. As a retrospective real-world analysis, it demonstrates association rather than causation, may reflect residual unmeasured confounding, and did not assess safety outcomes. The cardiovascular analysis included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, drawn from 636,525 adults initially receiving semaglutide 1 mg.",
    "product": "retrospective US claims analysis",
    "summary": "Novo Nordisk released a retrospective US claims analysis showing that adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg had a 6% lower adjusted MACE risk than those who switched to tirzepatide.",
    "planning": false,
    "image_url": "https://cdn.sanity.io/images/0vv8moc6/hcplive/e85a7cf1f7ca4d29bbeba692a932615307d507cc-1200x630.png",
    "confidence": 0.9,
    "product_data": {
      "name": "retrospective US claims analysis",
      "full_text": "retrospective US claims analysis",
      "fuzzy_match": false
    },
    "product_tags": [
      "report",
      "medical",
      "data"
    ],
    "published_at": "2026-09-29T12:38:46Z",
    "article_sentence": "In a retrospective US claims analysis, adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg had a 6% lower adjusted MACE risk than those who switched to tirzepatide, according to Novo Nordisk (adjusted HR, 1.06; 95% CI, 1.04–1.08)."
  }
}

curl https://signals.autobound.ai/v1/signals/20f6da2e-43b3-61da-21d2-bf8b77b9bf2f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'